View Older Stories View More Recent Stories

Jan 13, 2026 07:11AM Apellis Pharmaceuticals (APLS) PT Lowered to $28 at Needham
Jan 13, 2026 07:11AM Apellis Pharmaceuticals (APLS) Reiterated at Overweight by Cantor Fitzgerald
Jan 12, 2026 01:45PM Goldman Sachs on Apellis Pharmaceuticals (APLS): 'we see limited near-term growth levers'
Jan 2, 2026 10:00PM Here are Mizuho's top Biotech pick for 2026
Dec 21, 2025 08:00PM Here's the list of top biotech stocks to own for 2026
Dec 19, 2025 07:31AM Apellis Pharmaceuticals (APLS) PT Lowered to $48 at Stifel - Aims to Grow in 2026
Dec 15, 2025 04:30AM William Blair Reiterates Outperform Rating on Apellis Pharmaceuticals (APLS)
Nov 12, 2025 07:02AM Apellis reports SYFOVRE delayed geographic atrophy progression by 1.5 years
Nov 3, 2025 06:41AM Apellis Pharmaceuticals (APLS) PT Lowered to $19 at Mizuho
Oct 30, 2025 08:17AM Apellis Pharmaceuticals, Inc. (APLS) Tops Q3 EPS by 12c
Oct 21, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)
Oct 20, 2025 05:12AM Apellis Pharmaceuticals (APLS) PT Raised to $29 at BofA Securities
Oct 20, 2025 05:08AM Apellis Pharmaceuticals (APLS) PT Raised to $22 at RBC Capital
Oct 15, 2025 05:11AM Wells Fargo Upgrades Apellis Pharmaceuticals (APLS) to Overweight
Sep 29, 2025 06:58AM H.C. Wainwright Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)
Sep 26, 2025 05:08AM Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) to Sell
Aug 1, 2025 08:40AM Apellis Pharmaceuticals (APLS) PT Raised to $40 at Cantor Fitzgerald
Jul 31, 2025 07:09AM Apellis Pharmaceuticals, Inc. (APLS) Tops Q2 EPS by 15c
Jul 30, 2025 08:34AM Apellis Pharmaceuticals (APLS) PT Raised to $22 at Scotiabank
Jul 29, 2025 12:12PM Apellis Pharmaceuticals (APLS) PT Raised to $21 at Mizuho
Jul 29, 2025 08:36AM Cantor Fitzgerald Reiterates Overweight Rating on Apellis Pharmaceuticals (APLS)
Jul 29, 2025 07:07AM FDA approves Apellis' EMPAVELI as first C3G and primary IC-MPGN treatment
Jul 14, 2025 06:56AM H.C. Wainwright Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)
Jul 10, 2025 07:28AM William Blair Reiterates Outperform Rating on Apellis Pharmaceuticals (APLS)
Jul 10, 2025 06:40AM Cantor Fitzgerald Reiterates Overweight Rating on Apellis Pharmaceuticals (APLS)
Jul 2, 2025 06:36AM Mizuho Reiterates Neutral Rating on Apellis Pharmaceuticals (APLS)
Jul 1, 2025 12:03PM William Blair Reiterates Outperform Rating on Apellis Pharmaceuticals (APLS)
Jul 1, 2025 07:03AM Apellis Pharmaceuticals (APLS) to Receive up to $300M from Royalty Purchase Agreement with Sobi
Jun 6, 2025 09:16AM Apellis Pharmaceuticals (APLS) and Sobi announce data from EMPALEVI study, showing efficacy
Jun 2, 2025 05:53AM Apellis Pharmaceuticals (APLS) PT Raised to $29 at Wells Fargo
May 25, 2025 03:00PM Biotech stocks Q1 earnings review
May 21, 2025 04:54PM Apellis Pharmaceuticals (APLS) PT Lowered to $41 at Citi, Opens 90-Day Upside Catalyst Watch
May 9, 2025 05:16AM Raymond James Downgrades Apellis Pharmaceuticals (APLS) to Outperform
May 7, 2025 07:08AM Apellis Pharmaceuticals, Inc. (APLS) Misses Q1 EPS by 40c
Apr 29, 2025 06:32AM Cantor Fitzgerald Starts Apellis Pharmaceuticals (APLS) at Overweight
Apr 21, 2025 07:02AM Apellis Pharmaceuticals (APLS) Appoints Craig Wheeler to its Board
Apr 1, 2025 07:01AM Apellis Pharmaceuticals (APLS) Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
Mar 3, 2025 07:56AM Apellis Pharmaceuticals (APLS) PT Lowered to $75 at Raymond James
Feb 28, 2025 03:25PM Apellis Pharmaceuticals (APLS) PT Lowered to $60 at Stifel
Feb 28, 2025 03:06PM TD Cowen Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)
Feb 28, 2025 07:11AM Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 EPS by 8c
Feb 13, 2025 06:02AM Raymond James Reiterates Strong Buy Rating on Apellis Pharmaceuticals (APLS)
Feb 12, 2025 09:55AM Piper Sandler on Apellis Pharmaceuticals (APLS): 'GA Doc Survey Suggests GA Market Growth In Doubt'
Jan 28, 2025 12:16PM Mizuho Reiterates Neutral Rating on Apellis Pharmaceuticals (APLS)
Jan 27, 2025 04:00PM Apellis Pharmaceuticals (APLS) Receives Approval of SYFOVRE in Australia for Geographic Atrophy
Jan 13, 2025 09:07AM Apellis Pharmaceuticals (APLS) Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
Jan 10, 2025 07:02AM Apellis Pharmaceuticals (APLS) Announces Keli Walbert to Join the Board of Directors
Jan 7, 2025 09:03AM Apellis Pharmaceuticals (APLS) PT Raised to $26 at RBC Capital
Dec 17, 2024 05:10AM Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) to Neutral
Nov 21, 2024 04:25AM Morgan Stanley Starts Apellis Pharmaceuticals (APLS) at Equalweight
View More Recent Stories View Older Stories